Esfahani K - Search Results

1

Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.

Esfahani K, Buhlaiga N, Thébault P, Lapointe R, Johnson NA, Miller WH Jr. Esfahani K, et al. N Engl J Med. 2019 Jun 13;380(24):2375-2376. doi: 10.1056/NEJMc1903064. N Engl J Med. 2019. PMID: 31189042 No abstract available.

2

Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.

Ferrario C, Strepponi I, Esfahani K, Charamis H, Langleben A, Scarpi E, Nanni O, Miller WH Jr, Panasci LC. Ferrario C, et al. Among authors: esfahani k. PLoS One. 2016 Dec 19;11(12):e0167906. doi: 10.1371/journal.pone.0167906. eCollection 2016. PLoS One. 2016. PMID: 27992451 Free PMC article. Clinical Trial.

3

Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade.

Esfahani K, Miller WH Jr. Esfahani K, et al. N Engl J Med. 2017 May 18;376(20):1989-91. doi: 10.1056/NEJMc1703047. N Engl J Med. 2017. PMID: 28514612 No abstract available.

4

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma.

Meti N, Esfahani K, Johnson NA. Meti N, et al. Among authors: esfahani k. Cancers (Basel). 2018 Jun 15;10(6):204. doi: 10.3390/cancers10060204. Cancers (Basel). 2018. PMID: 29914088 Free PMC article. Review.

5

Adverse events associated with immune checkpoint inhibitor treatment for cancer.

Esfahani K, Meti N, Miller WH Jr, Hudson M. Esfahani K, et al. CMAJ. 2019 Jan 14;191(2):E40-E46. doi: 10.1503/cmaj.180870. CMAJ. 2019. PMID: 30642824 Free PMC article. Review. No abstract available.

6

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation.

Esfahani K, Al-Aubodah TA, Thebault P, Lapointe R, Hudson M, Johnson NA, Baran D, Bhulaiga N, Takano T, Cailhier JF, Piccirillo CA, Miller WH. Esfahani K, et al. Nat Commun. 2019 Oct 17;10(1):4712. doi: 10.1038/s41467-019-12628-1. Nat Commun. 2019. PMID: 31624262 Free PMC article.

7

Moving towards personalized treatments of immune-related adverse events.

Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH Jr, Calabrese L. Esfahani K, et al. Nat Rev Clin Oncol. 2020 Aug;17(8):504-515. doi: 10.1038/s41571-020-0352-8. Epub 2020 Apr 3. Nat Rev Clin Oncol. 2020. PMID: 32246128 Review.

8

A review of cancer immunotherapy: from the past, to the present, to the future.

Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH Jr. Esfahani K, et al. Curr Oncol. 2020 Apr;27(Suppl 2):S87-S97. doi: 10.3747/co.27.5223. Epub 2020 Apr 1. Curr Oncol. 2020. PMID: 32368178 Free PMC article. Review.

9

Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy.

Esfahani K, Hudson M, Batist G. Esfahani K, et al. N Engl J Med. 2020 Jun 11;382(24):2374-2375. doi: 10.1056/NEJMc2002527. N Engl J Med. 2020. PMID: 32521140 No abstract available.

10

Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report.

Esfahani K, Henderson Berg MH, Zargham H, Billick R, Pehr K, Redpath M, Roshdy O, Miller WH. Esfahani K, et al. J Immunother Cancer. 2021 Mar;9(3):e001831. doi: 10.1136/jitc-2020-001831. J Immunother Cancer. 2021. PMID: 33771890 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

51 results

Search Page